Dupixent & Cutaneous T-Cell Lymphoma (CTCL): What Patients Need to Know Featured
Reports link Dupixent to T-cell lymphomas; see eligibility and evidence
Why Lawsuits Are Being Filed
Patients across the U.S. are filing lawsuits alleging that Dupixent® (dupilumab)—prescribed for eczema, asthma, nasal polyps, and other conditions—may trigger, worsen, or mask a cancer of the immune system called cutaneous T-cell lymphoma (CTCL). Core claims focus on whether the manufacturers failed to provide adequate warnings and whether CTCL symptoms were mistaken for eczema, delaying diagnosis and treatment.
Important: There is no certified class action right now. Most claims are currently being filed as individual cases and may be coordinated in a multidistrict litigation (MDL).
What Recent Investigations Show
- September 2025: The FDA announced a formal safety investigation into reports of CTCL in Dupixent users and is evaluating whether new cancer warnings should be added.
- October 2025: The first wrongful-death lawsuit was filed by the family of a Tennessee woman who developed T-cell lymphoma shortly after starting Dupixent.
- Multiple research teams (2024–2025) report that patients treated with dupilumab for atopic dermatitis showed ~4x or higher rates of CTCL compared to non-dupilumab patients, with many diagnoses occurring within the first year of therapy.
CTCL Red Flags Patients Reported
- Red, scaly patches or thick plaques that don’t improve as expected
- Persistent itching or pain, new nodules, or tumors on the skin
- Swollen lymph nodes, fatigue, or unexplained weight loss
If you’re experiencing unusual or worsening skin changes while on Dupixent, ask your dermatologist about a skin biopsy with immunophenotyping to rule out CTCL.
Who May Qualify to File
You may qualify for a claim if you:
- Were treated with Dupixent (after 2017) for eczema, asthma, nasal polyps, COPD, or other approved indications; and
- Were later diagnosed with CTCL or a related T/NK-cell lymphoma (e.g., mycosis fungoides, Sézary syndrome); or
- Experienced a worsening or “unmasking” of lymphoma symptoms that resembled eczema while on Dupixent.
Helpful evidence includes dermatology notes, biopsy/pathology reports, Dupixent start/stop dates, and documentation of disease progression.
Potential Compensation
Successful cases may recover damages for:
- Medical expenses (past and future)
- Lost wages or diminished earning capacity
- Pain and suffering and loss of quality of life
- Wrongful death damages for eligible families
Case value depends on warning adequacy, medical severity and staging, timing of diagnosis, and venue. Every case is fact-specific; results vary.
How the Legal Process Works
- Free, confidential review: Share your treatment history and key medical records.
- Investigation: Attorneys consult dermatology/hematopathology experts.
- Filing: Your claim is filed in the appropriate court; cases may be coordinated.
- Discovery & negotiation: Evidence is exchanged; settlement or trial follows.
Start Your Free Claim Review
If you or a loved one used Dupixent and were later diagnosed with CTCL (or suspect CTCL), you may have a claim. Start your free, no-obligation case review today. Simply complete the form shown on this page and an attorney will contact you to discuss your claim. There are no upfront fees.
Medical disclaimer: This page is for informational purposes only and is not medical advice. Always consult your physician about diagnosis or treatment. Legal outcomes are not guaranteed.